Katie Hobbins - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Katie Hobbins's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Katie Hobbins
Verified
Managing Editor, Medical Device and Diagnostic Industry (MDDI)
United States
Beats
Biography
Katie Hobbins is a journalist that graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. You can reach her at katie.hobbins@informa.com
Lifestyle Topics, Marketing Tips, Mental health, Enneagram, Amazon Products, Instagram Tips, Home decor, Sustainability, Health and Beauty
fluffy, bunnies
Content
By Katie Hobbins Verified| Medical Device and Diagnostic Industry (MDDI) Verified SeaStar Medical Holdings, a medtech company developing solutions to reduce the consequences of hyperinflammation on vital organs, recently announced it had obtained FDA Breakthrough Device Designation for its patented Selective Cytopheretic Device (SCD) for use in hepatorenal syndrome patients in the ICU. The hepatorenal syndrome designation becomes the company’s third for the SCD device, along with adult acute kidney injury (AKI) and cardiorenal syndrome.
By Katie Hobbins Verified| Medical Device and Diagnostic Industry (MDDI) Verified Medical technology company Haemonetics has entered into a definitive agreement to acquireOpSens, a medical device company focused on cardiology. Haemonetics will acquire the company by buying all outstanding shares for CAD $2.90 per share in an all-cash transaction “representing a fully diluted equity value of approximately USD $253 million at current exchange rate,” according to the press release.
By Katie Hobbins Verified| Medical Device and Diagnostic Industry (MDDI) Verified SeaStar Medical Holdings, a medtech company developing solutions to reduce the consequences of hyperinflammation on vital organs, recently announced it had obtained FDA Breakthrough Device Designation for its patented Selective Cytopheretic Device (SCD) for use in hepatorenal syndrome patients in the ICU. The hepatorenal syndrome designation becomes the company’s third for the SCD device, along with adult acute kidney injury (AKI) and cardiorenal syndrome.
Company Info
Medical Device and Diagnostic Industry (MDDI)
London, England, United Kingdom
'+44 20 8052 0400